ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…
Read MoreST. LOUIS, April 30, 2019 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., as Vice President of Finance…
Read MoreST. LOUIS, March 26, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as Vice President of Research and…
Read MoreST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings…
Read MoreST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…
Read MoreST. LOUIS, Nov. 13, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…
Read MoreST. LOUIS, Nov. 1, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…
Read MoreCopyright © 2024 Wugen. All Rights Reserved.
a COGNEO design
